Letter from the editor.
Reichert
Janice M
JM
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001847:Bone Diseases / Q000188:drug therapy* / Q000276:immunology; D002170:Canada; D017277:Drug Approval; D005060:Europe; D006801:Humans; D007880:Legislation, Drug; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D010330:Patents as Topic; D015202:Protein Engineering; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D014481:United States; D014777:Virus Diseases / Q000188:drug therapy* / Q000276:immunology
D000911:Antibodies, Monoclonal; D011993:Recombinant Fusion Proteins